424B4CIK 0001806540
Lycia Therapeutics, Inc.
Final prospectus (424B4) filed .
Final prospectus filed under Rule 424(b)(4) that includes the pricing and related information omitted from the registration statement at effectiveness — the common final prospectus for IPOs and public offerings.
Filing facts
- Accession number
- 0001628280-26-067048
- Filer
- Lycia Therapeutics, Inc.
- CIK
- 0001806540
- Form type
- 424B4
- Form description
- Final prospectus
- Filed at
- October 23, 2026
- Industry
- SIC 2836Biological Products
- Last verified
- October 23, 2026SecFilingDex pulls from EDGAR with daily cadence
More filings from Lycia Therapeutics, Inc.
Provenance
Authoritative source — SEC EDGAR
https://www.sec.gov/Archives/edgar/data/1806540/000162828026067048/0001628280-26-067048-index.htm ↗Filer's full EDGAR submission history
EDGAR · Lycia Therapeutics, Inc. (0001806540) ↗Machine-readable JSON twin (LLM-citation friendly)
/api/filing/0001628280-26-067048.jsonSecFilingDex republishes SEC EDGAR data with provenance. EDGAR is the authoritative source. SecFilingDex is independent and not affiliated with the U.S. Securities and Exchange Commission. Nothing on this page constitutes investment, legal, tax, or other professional advice.